plerixafor + rituximab

plerixafor + rituximab is a combination therapy comprising **plerixafor**, a small molecule CXCR4 (C-X-C chemokine receptor type 4) antagonist, and **rituximab**, a monoclonal antibody targeting the CD20 antigen on B cells. Plerixafor works by blocking the interaction between CXCR4 and its ligand CXCL12, thereby mobilizing hematopoietic stem cells and disrupting the tumor microenvironment protective niche for malignant B cells. Rituximab binds specifically to CD20 on B lymphocytes, leading to their destruction via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis. When used together, preclinical and early clinical studies demonstrate **synergistic anti-tumor effects**—enhanced apoptosis and growth inhibition—likely owing to increased tumor cell sensitization and improved accessibility of B cells to rituximab consequent to CXCR4 blockade[1][3]. This combination has been studied in diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL) for its potential to augment rituximab efficacy, reduce drug resistance, and allow dose reduction[1].

Other names

plerixafor + rituximabCXCR4 antagonist + anti-CD20 antibody